PHARMACOKINETICS AND DRUG DISPOSITION St John’s Wort: Effect on CYP3A4 activity

St John's Wort is a widely used herbal product. Information regarding its potential for drug interactions is required for responsible treatment of patients using St John's Wort. CYP3A4 is a metabolic enzyme implicated in most clinically significant drug‐drug interactions.

[1]  F. Ruschitzka,et al.  Acute heart transplant rejection due to Saint John's wort , 2000, The Lancet.

[2]  S. Risch,et al.  Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.

[3]  E. Ernst,et al.  Second thoughts about safety of St John's wort , 1999, The Lancet.

[4]  I. Roots,et al.  Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.

[5]  T. Rebbeck Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4 , 1999 .

[6]  P. Hopkins,et al.  Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.

[7]  S. J. Kovacs,et al.  Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction , 1999, Journal of clinical pharmacology.

[8]  D. Kroll,et al.  Potential Metabolic Interaction between St. John's Wort and Theophylline , 1999, The Annals of pharmacotherapy.

[9]  M J Cupp,et al.  Herbal remedies: adverse effects and drug interactions. , 1999, American family physician.

[10]  R. Tackett,et al.  St. John's wort: a new alternative for depression? , 1999, International journal of clinical pharmacology and therapeutics.

[11]  M. Klepser,et al.  Unsafe and potentially safe herbal therapies. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  S. London,et al.  CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. , 1998, Pharmacogenetics.

[13]  D. Smith,et al.  Human cytochrome P450s: selectivity and measurement in vivo. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  A. Burstein,et al.  Cytochrome P450 3A4 Activity in Premenopausal and Postmenopausal Women, Based on 6‐β‐Hydroxycortisol:Cortisol Ratios , 1998, Pharmacotherapy.

[15]  H. Boon,et al.  Herbal remedies in psychiatric practice. , 1998, Archives of general psychiatry.

[16]  J. Chaffin,et al.  Herbal 'health' products: what family physicians need to know. , 1998, American family physician.

[17]  D. Jorkasky,et al.  Urinary excretion of 6β‐hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations , 1998, Clinical pharmacology and therapeutics.

[18]  E. Heiligenstein,et al.  Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian, and kava-kava. , 1998, Journal of American college health : J of ACH.

[19]  Elizabeth Landrum Michalets,et al.  Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.

[20]  B C Eliason,et al.  Dietary Supplement Users: Demographics, Product Use, and Medical System Interaction , 1997, The Journal of the American Board of Family Medicine.

[21]  J. Brockmöller,et al.  Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin , 1996, Antimicrobial agents and chemotherapy.

[22]  P. D. Smet Health Risks of Herbal Remedies , 1995 .

[23]  T. Bienvenu,et al.  A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. , 1991, International journal of clinical pharmacology, therapy, and toxicology.

[24]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[25]  P. Beaune,et al.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. , 1989, British journal of clinical pharmacology.

[26]  P. Watkins,et al.  Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.

[27]  G. Zaccara,et al.  Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. , 1987, Pharmacological research communications.

[28]  P. Saenger 6β‐Hydroxycortisol in random urine samples as an indicator of enzyme induction , 1983 .

[29]  L. Harries,et al.  Molecular genetics of the human cytochrome P450 monooxygenase superfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  H. Hippius St John's Wort (Hypericum perforatum)--a herbal antidepressant. , 1998, Current medical research and opinion.

[31]  U. Mansmann,et al.  Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. , 1997, International journal of clinical pharmacology and therapeutics.

[32]  P. D. de Smet Health risks of herbal remedies. , 1995, Drug safety.